Document Classification

Section Type: METHODS

Text: After 1 week placebo lead-in, 67 subjects were randomized into one of four treatment sequences : sequence A (n = 15) Org 26576 (100 mg b. i. d.) for 3 weeks, followed by a 2-week placebo crossover and 3 weeks placebo ; sequence B (n = 16) 5 weeks placebo followed by 3 weeks Org 26576 (100 mg b. i. d.) ; sequence C (n = 18) Org 26576 flexible dose (100-300 mg b. i. d.) for 3 weeks, then 5 weeks placebo ; sequence D (n = 18) 5 weeks placebo followed by 3 weeks Org 26576 (100-300 mg b. i. d.).